AZN.UK

10,426

+0.71%↑

GSK

1,425.5

+0.11%↑

AZN.UK

10,426

+0.71%↑

GSK

1,425.5

+0.11%↑

AZN.UK

10,426

+0.71%↑

GSK

1,425.5

+0.11%↑

AZN.UK

10,426

+0.71%↑

GSK

1,425.5

+0.11%↑

AZN.UK

10,426

+0.71%↑

GSK

1,425.5

+0.11%↑

Search

Indivior PLC

Cerrado

826 -0.42

Resumen

Variación precio

24h

Actual

Mínimo

817

Máximo

848.5

Métricas clave

By Trading Economics

Ingresos

-19M

47M

Ventas

-33M

266M

P/B

Media del Sector

330

54.533

BPA

0.41

Margen de beneficio

17.669

Empleados

1,030

EBITDA

-30M

76M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 meses

+22.06% upside

Dividendos

By Dow Jones

Próximas Ganancias

24 jul 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

259M

1.1B

Apertura anterior

826.42

Cierre anterior

826

Indivior PLC Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

23 may 2025, 20:33 UTC

Adquisiciones, fusiones, absorciones

Salesforce in Talks to Buy Informatica, Bloomberg Reports, Citing Sources

23 may 2025, 21:57 UTC

Acciones populares

Stocks to Watch: Apple, Booz Allen, Constellation Energy, Intuit -- WSJ

23 may 2025, 21:15 UTC

Principales Noticias

Trump Threatens Fresh Tariffs on EU, iPhones and Rival Devices -- 4th Update

23 may 2025, 21:04 UTC

Adquisiciones, fusiones, absorciones

Real-Estate Broker Douglas Elliman Could See Takeover Battle After Report of Bid -- Barrons.com

23 may 2025, 20:56 UTC

Principales Noticias
Adquisiciones, fusiones, absorciones

Salesforce Back in Deal Talks With Informatica -- WSJ

23 may 2025, 20:51 UTC

Principales Noticias

Boeing in Tentative Agreement to Pay $1.1 Billion to Avoid Trial for 737 MAX Crashes -- WSJ

23 may 2025, 20:50 UTC

Charlas de Mercado

Auto & Transport Roundup: Market Talk

23 may 2025, 20:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

23 may 2025, 20:41 UTC

Principales Noticias

Stocks Fall on Tariff Broadside, After Week of Bond Market Agita -- WSJ

23 may 2025, 20:28 UTC

Principales Noticias

Trump Threatens EU With 50% Tariffs, Takes Aim at Apple; Nasdaq Drops -- WSJ

23 may 2025, 20:06 UTC

Principales Noticias

Trump Threatens Fresh Tariffs on EU, iPhones and Rival Devices -- 5th Update

23 may 2025, 20:06 UTC

Adquisiciones, fusiones, absorciones

Salesforce Stock Drops, Informatica Soars. A Deal May Be Back on the Table. -- Barrons.com

23 may 2025, 19:50 UTC

Principales Noticias

Trump's Tariffs: Where Things Stand -- 16th Update

23 may 2025, 19:28 UTC

Adquisiciones, fusiones, absorciones

Trump on Truth Social: 'Bulk of That Investment Will Occur in the Next 14 Months'

23 may 2025, 19:28 UTC

Adquisiciones, fusiones, absorciones

Trump on Truth Social: 'This Will Be a Planned Partnership Between United States Steel and Nippon Steel'

23 may 2025, 19:27 UTC

Adquisiciones, fusiones, absorciones

Trump on Truth Social: 'Proud to Announce That, After Much Consideration and Negotiation, US Steel Will REMAIN in America'

23 may 2025, 19:20 UTC

Charlas de Mercado

Crude Futures Post Modest Weekly Losses -- Market Talk

23 may 2025, 19:18 UTC

Charlas de Mercado

U.S. Natural Gas Futures End Week Unchanged -- Market Talk

23 may 2025, 18:57 UTC

Principales Noticias

Trump Threatens Fresh Tariffs on EU, iPhones and Rival Devices -- 4th Update

23 may 2025, 18:54 UTC

Principales Noticias

Trump Threatens Fresh Tariffs on EU, iPhones and Rival Devices -- Update

23 may 2025, 18:53 UTC

Principales Noticias
Adquisiciones, fusiones, absorciones

McDonald's Bids Goodbye to CosMc's, Its Space Alien-Themed Spinoff -- WSJ

23 may 2025, 18:52 UTC

Adquisiciones, fusiones, absorciones

DDC Enterprise Issues 254,333 Class A Ordinary Shrs in Exchange for 21 BTC, Valued at About $2.28M in Current Market Price

23 may 2025, 18:13 UTC

Charlas de Mercado

Market Talk Roundup: Latest on U.S. Politics

23 may 2025, 18:13 UTC

Charlas de Mercado

Gold Trades Higher on Reminder of Risk -- Market Talk

23 may 2025, 18:00 UTC

Principales Noticias

Apple's Stock Still Not Pricing in Trump's Demands - Heard on the Street -- WSJ

23 may 2025, 17:51 UTC

Charlas de Mercado
Ganancias

Workday Sees Higher Bar for Guidance -- Market Talk

23 may 2025, 17:42 UTC

Principales Noticias

Dow Drops, Trump Threatens EU With 50% Tariffs, Takes Aim at Apple -- WSJ

23 may 2025, 17:39 UTC

Charlas de Mercado

U.S. Oil Rig Count Falls to Lowest Level Since November 2021 -- Market Talk

23 may 2025, 17:07 UTC

Principales Noticias

Trump's Tariffs: Where Things Stand -- 15th Update

23 may 2025, 17:04 UTC

Charlas de Mercado
Ganancias

Workday Appears to Have Upside Potential on Conservative Outlook -- Market Talk

Comparación entre iguales

Cambio de precio

Indivior PLC Esperado

Precio Objetivo

By TipRanks

22.06% repunte

Estimación a 12 meses

Media 1,014.32 GBX  22.06%

Máximo 1,100 GBX

Mínimo 967.968 GBX

De acuerdo con 4 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Indivior PLC Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

4 ratings

4

Comprar

0

Mantener

0

Vender

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Indivior PLC

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose. Its core marketed products include SUBLOCADE and SUBUTEX PRO buprenorphine extended-release monthly injections; SUBOXONE, a buprenorphine and naloxone sublingual film; SUBOXONE, a buprenorphine and naloxone sublingual tablet; and SUBUTEX, a buprenorphine sublingual tablet for the treatment of opioid use disorder. The company also offers OPVEE nasal spray for opioid overdose reversal; and PERSERIS extended-release injectable suspension for the treatment of schizophrenia in adults. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that completed phase 1 clinical trial for the treatment of opioid use disorder (OUD); INDV-1000, a selective GABAb positive allosteric modulator, which is in pre-clinical development phase for the treatment of alcohol use disorder in collaboration with ADDEX therapeutics; INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc.; and CT-102, a digital therapeutic for the treatment of OUD in collaboration with Click Therapeutics. Further, the company is developing INDV-5004, a drinabant injection to treat acute cannabinoid overdose. It has a strategic partnership with Aelis Farma to develop AEF0117, a synthetic CB1 specific signaling inhibitor that is in phase 2B clinical trial for the treatment of cannabis use disorder. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.